1-(2-氯乙基)-5-硝基-1H-咪唑 | 13182-80-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(2-氯乙基)-5-硝基-1H-咪唑
• 英文名称: 1-(2-chloroethyl)-5-nitro-1H-imidazole
• 英文别名: 1-(2-chloro-ethyl)-5-nitro-1H-imidazole；1-(β-Chlorethyl)-5-nitroimidazol；1-(2-Chlorethyl)-5-nitro-imidazol；1-(2-Chloroethyl)-5-nitroimidazole
• CAS: 13182-80-4
• 化学式: C₅H₆ClN₃O₂
• 分子量: 175.575
• InChiKey: UDSKWVHYNOSUOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-氯乙基)-5-硝基-1H-咪唑 在 palladium on activated charcoal 氢气 、 sodium ethanolate 、 碳酸氢钠 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 1.0h， 生成 5-amino-3-vinyl-3H-imidazo[4,5-b]pyridine-6-carbonitrile
  参考文献：
  名称：

  Routes toN-vinyl-nitroimidazoles andN-vinyl-deazapurines

  摘要：

  AbstractThe preparations of 4‐ and 5‐nitro‐1‐vinylimidazole (2 and 7) are described. Selective reduction of the nitro group using Fe/dil.HCl is achieved for the 4‐nitro derivative but this is not effective when ethoxymethylenemalononitrile is used to trap the amine. For 5‐nitroimidazole studies the N‐vinyl substituent is kept masked as a 2‐chloroethyl group, which remains unchanged during catalytic reduction of the nitro function (Pd/C), and is revealed by HCl elimination at a later stage. In this way, the 1‐deazapurine 13 and the tricyclic derivative 14 have been prepared.

  DOI：

  10.1002/jhet.5570410508
• 作为产物：
  描述：

  二(2-氯乙基)硫酸酯 、 乙酸(4-硝基咪唑-1-基)甲酯 在 硫酸 作用下， 以 水 为溶剂， 反应 4.0h， 以74%的产率得到1-(2-氯乙基)-5-硝基-1H-咪唑
  参考文献：
  名称：

  Routes toN-vinyl-nitroimidazoles andN-vinyl-deazapurines

  摘要：

  AbstractThe preparations of 4‐ and 5‐nitro‐1‐vinylimidazole (2 and 7) are described. Selective reduction of the nitro group using Fe/dil.HCl is achieved for the 4‐nitro derivative but this is not effective when ethoxymethylenemalononitrile is used to trap the amine. For 5‐nitroimidazole studies the N‐vinyl substituent is kept masked as a 2‐chloroethyl group, which remains unchanged during catalytic reduction of the nitro function (Pd/C), and is revealed by HCl elimination at a later stage. In this way, the 1‐deazapurine 13 and the tricyclic derivative 14 have been prepared.

  DOI：

  10.1002/jhet.5570410508

文献信息

• N-aryl-N-[4-(heterocyclicalkyl) piperidinyl]amides and pharmaceutical compositions and methods employing such compounds
  申请人：BOC, INC.

  公开号：EP0396282A2

  公开（公告）日：1990-11-07

  Novel substituted N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides useful as analgesics, of the formula: including optically active isomeric forms, and the pharmaceutically acceptable acid addition salts thereof, wherein; R is selected from the group consisting of phenyl and substituted phenyl, wherein said substituents are members independently selected from halogen, lower-alkoxy, and combinations thereof; R₁ is a lower-alkyl group, lower-alkenyl group, or a lower-alkoxy lower alkyl having from 2 to 6 carbon atoms; R₂ is a heterocyclic lower-alkyl ring system selected from the group consisting of pyrrolyl lower-alkyl, pyrazolyl lower-alkyl, imidazolyl lower-alkyl, imidazolinyl lower-alkyl, imidazolyl lower-thioalkyl, triazolyl lower-alkyl, triazolyl lower-thioalkyl, tetrazolyl lower-alkyl, tetrazolyl lower-thioalkyl, thienyl lower-oxyalkyl, thienyl lower- hydroxyalkyl, thien-3-yl lower-alkyl, furanyl lower-hydroxyalkyl, thiazolyl lower-alkyl, oxazolyl lower-alkyl, thiadiazolyl lower-alkyl, oxadiazolyl lower-alkyl, piperidinyl loweralkyl, pyrimidinyl lower- alkyl, pyridazinyl lower-alkyl, triazinyl lower-alkyl, indolyl lower-alkyl, isoindolyl lower-alkyl, benzimidazolyl lower-alkyl, benzopyrazolyl lower-alkyl, benzoxazolyl lower-alkyl, benzopyranyl lower-alkyl, benzodioxanyl lower-alkyl, benzothiazinyl lower-alkyl, quinazolinyl lower-alkyl, purinyl lower-alkyl, phthalimidyl lower-alkyl, naphthalenecarboxamidyl lower-alkyl, and naphthalenesulfamidyl lower-alkyl; and R₃ is a member selected from the group consisting of hydrogen, lower-alkoxy carbonyl and lower-alkoxy methyl. R₄ is a hydrogen atom or a methyl group;

  可用作镇痛剂的新型取代 N-芳基-N-[4-(1-杂环烷基)哌啶基]酰胺，其式如下 包括光学活性异构体形式及其药学上可接受的酸加成盐，其中； R 选自苯基和取代苯基组成的组，其中所述取代基独立地选自卤素、低级烷氧基及其组合； R₁ 是具有 2 至 6 个碳原子的低级烷基、低级烯基或低级烷氧基； R₂ 是杂环低级烷基环系，选自由吡咯低级烷基、吡唑低级烷基、咪唑低级烷基、咪唑啉低级烷基、咪唑低级硫代烷基、三唑低级烷基组成的组、三唑基低硫代烷基、四唑基低烷基、四唑基低硫代烷基、噻吩基低氧代烷基、噻吩基低羟代烷基、噻吩-3-基低烷基、呋喃基低羟代烷基、噻唑基低烷基、噁唑基低烷基、噻二唑基低烷基、噁二唑低级烷基、哌啶低级烷基、嘧啶低级烷基、哒嗪低级烷基、三嗪低级烷基、吲哚低级烷基、异吲哚低级烷基、苯并咪唑低级烷基、苯并吡唑低级烷基、苯并恶唑低级烷基、低级烷基苯并吡喃基、低级烷基苯并二恶烷基、低级烷基苯并噻嗪基、低级烷基喹唑啉基、低级烷基嘌呤基、低级烷基邻苯二甲酰亚胺基、低级烷基萘甲酰胺基和低级烷基萘磺酰胺基；和 R₃ 选自氢、低级烷氧基羰基和低级烷氧基甲基组成的组。 R₄ 是氢原子或甲基；
• SEHGAL R. K.; AGRAWAL K. C., J. HETEROCYCL. CHEM., 1979, 16, NO 5, 871-876
  作者：SEHGAL R. K.、 AGRAWAL K. C.

  DOI：——

  日期：——
• US3962274A
  申请人：——

  公开号：US3962274A

  公开（公告）日：1976-06-08
• US3997572A
  申请人：——

  公开号：US3997572A

  公开（公告）日：1976-12-14
• US5053411A
  申请人：——

  公开号：US5053411A

  公开（公告）日：1991-10-01